Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole monotherapy in adolescents with schizophrenia
2017-001447-12Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brexpiprazole in schizophrenia (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Change from baseline to Week 6 in PANSS Total Score. Started Oct 2018; status: completed.
02
Drugs
brexpiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2017-001447-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001447-12.